LAB Cash-Secured Put Strategy
LAB (Standard BioTools Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.
LAB (Standard BioTools Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $394.3M, a trailing P/E of 5.01, a beta of 1.31 versus the broader market, a 52-week range of 0.87-1.72, average daily share volume of 2.6M, a public-listing history dating back to 2011, approximately 814 full-time employees. These structural characteristics shape how LAB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.31 indicates LAB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 5.01 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a cash-secured put on LAB?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current LAB snapshot
As of May 13, 2026, spot at $1.00, ATM IV 117.10%, IV rank 21.43%, expected move 22.00%. The cash-secured put on LAB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 36-day expiry.
Why this cash-secured put structure on LAB specifically: LAB IV at 117.10% is on the cheap side of its 1-year range, which means a premium-selling LAB cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 22.00% (roughly $0.22 on the underlying). The 36-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LAB expiries trade a higher absolute premium for lower per-day decay. Position sizing on LAB should anchor to the underlying notional of $1.00 per share and to the trader's directional view on LAB stock.
LAB cash-secured put setup
The LAB cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LAB near $1.00, the first option leg uses a $0.95 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LAB chain at a 36-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LAB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $0.95 | N/A |
LAB cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
LAB cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on LAB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on LAB
Cash-secured puts on LAB earn premium while a trader waits to acquire LAB stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning LAB.
LAB thesis for this cash-secured put
The market-implied 1-standard-deviation range for LAB extends from approximately $0.78 on the downside to $1.22 on the upside. A LAB cash-secured put lets a trader earn premium while waiting to acquire LAB at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current LAB IV rank near 21.43% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LAB at 117.10%. As a Healthcare name, LAB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LAB-specific events.
LAB cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LAB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LAB alongside the broader basket even when LAB-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on LAB carry tail risk when realized volatility exceeds the implied move; review historical LAB earnings reactions and macro stress periods before sizing. Always rebuild the position from current LAB chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on LAB?
- A cash-secured put on LAB is the cash-secured put strategy applied to LAB (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With LAB stock trading near $1.00, the strikes shown on this page are snapped to the nearest listed LAB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LAB cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the LAB cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 117.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LAB cash-secured put?
- The breakeven for the LAB cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LAB market-implied 1-standard-deviation expected move is approximately 22.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on LAB?
- Cash-secured puts on LAB earn premium while a trader waits to acquire LAB stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning LAB.
- How does current LAB implied volatility affect this cash-secured put?
- LAB ATM IV is at 117.10% with IV rank near 21.43%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.